[1]Thanindratarn P,Dean DC,Nelson SD,et al.Advances in immune checkpoint inhibitors for bone sarcoma therapy[J].J Bone Oncol,2019(15):100221.
[2]李锋,龚继承,杜经柱,等.lncRNA FGD5-AS1调控miR-761影响骨肉瘤细胞增殖、迁移和凋亡的机制研究[J].实用骨科杂志,2021,27(3):228-234.
[3]Morice S,Danieau G,Rédini F,et al.Hippo/YAP Signaling Pathway:A Promising Therapeutic Target in Bone Paediatric Cancers?[J].Cancers,2020,12(3):645.
[4]Kovar H,Bierbaumer L,Radic-Sarikas B.The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis[J].Cells,2020,9(4):972.
[5]Chen YA,Lu CY,Cheng TY,et al.WW Domain-containing proteins yap and taz in the hippo pathway as key regulators in stemness maintenance,tissue homeostasis,and tumorigenesis[J].Front Oncol,2019(9):60.
[6]Zhang YH,Li B,Shen L,et al.The role and clinical significance of YES-associated protein 1 in human osteosarcoma[J].Int J Immunopathol Pharmacol,2013,26(1):157.
[7]Chan LH,Wang W,Yeung W,et al.Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression[J].Oncogene,2014,33(40):4857-66.
[8]Zucchini C,Manara MC,Cristalli C,et al.ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity[J].J Exp Clin Cancer Res,2019,38(1):503.
[9]Morice S,Mullard M,Brion R,et al.The YAP/TEAD axis as a new therapeutic target in osteosarcoma:Effect of verteporfin and CA3 on primary tumor growth[J].Cancers,2020,12(12):3847.
[10]Ma J,Huang K,Ma Y,et al.The TAZ-miR-224-SMAD4 axis promotes tumorigenesis in osteosarcoma[J].Cell Death Dis,2017,8(1):e2539.
[11]贾楠,张迎龙,刘涛,等.YAP和TAZ在骨肉瘤组织中的表达及临床意义[J].现代肿瘤医学,2015,23(22):3330-3.
[12]Bouvier C,Macagno N,Nguyen Q,et al.Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and beta 1-integrin in conventional osteosarcoma[J].Oncotarget,2016,7(40):64702-64710.
[13]Velletri T,Xie N,Wang Y,et al.P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development[J].Cell Death Dis,2016,7(1):e2015.
[14]Shin MH,He Y,Marrogi E,et al.A RUNX2-mediated epigenetic regulation of the survival of p53 defective cancer cells[J].PLoS Genet,2016,12(2):e1005884.
[15]Hong JH,Hwang ES,McManus MT,et al.TAZ,a transcriptional modulator of mesenchymal stem cell differentiation[J].Science,2005,309(5737):1074-1078.
[16]Goto H,Nishio M,To Y,et al.Loss of Mob1a/b in mice results in chondrodysplasia due to YAP1/TAZ-TEAD-dependent repression of SOX9[J].Development,2018,145(6):dev159244.
[17]Yang Z,Zhang M,Xu K,et al.Knockdown of YAP1 inhibits the proliferation of osteosarcoma cells in vitro and in vivo[J].Oncol Rep,2014,32(3):1265-1272.
[18]Liu G,Huang K,Jie Z,et al.CircFAT1 sponges miR-375 to promote the expression of Yes-associated protein 1 in osteosarcoma cells[J].Mol Cancer,2018,17(1):170.
[19]Luo Y,Liu W,Tang P,et al.miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells[J].J Exp Clin Cancer Res,2019,38(1):488.
[20]Luo Z,Wu G,Zhang D,et al.MicroRNA-625 targets Yes-associated protein 1 to suppress cell proliferation and invasion of osteosarcoma[J].Mol Med Rep,2018,17(1):2005-2011.
[21]Yi X,Deng X,Zhao Y,et al.Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1[J].Exp Cell Res,2020,387(2):111804.
[22]Chai J,Xu S,Guo F.TEAD1 mediates the oncogenic activities of Hippo-YAP1 signaling in osteosarcoma[J].Biochem Biophys Res Commun,2017,488(2):297-302.
[23]Shen S,Huang K,Wu Y,et al.A miR-135b-TAZ positive feedback loop promotes epithelial mesenchymal transition (EMT)and tumorigenesis in osteosarcoma[J].Cancer Lett,2017(407):32-44.
[24]Luu AK,Schott CR,Jones R,et al.An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression[J].BMC Vet Res,2018,14(1):365.
[25]Wang DY,Wu YN,Huang JQ,et al.Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance[J].Chin J Cancer,2016(35):47.
[26]Xu W,Chen C,Xu R,et al.Knockdown of HuR represses osteosarcoma cells migration,invasion and stemness through inhibition of YAP activation and increases susceptibility to chemotherapeutic agents[J].Biomed Pharmacother,2018(102):587-593.
[27]Jabbari E,Sarvestani SK,Daneshian L,et al.Optimum 3D matrix stiffness for maintenance of cancer stem cells is dependent on tissue origin of cancer cells[J].PLoS One,2015,10(7):e0132377.
[28]Coughlin TR,Sana A,Voss K,et al.The effect of fluid flow shear stress and substrate stiffness on yes-associated protein (YAP)activity and osteogenesis in murine osteosarcoma cells[J].Cancers,2021,13(13):3128.
[29]Lamhamedi-Cherradi SE,Mohiuddin S,Mishra DK,et al.Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation,cell fate,and metastasis in human osteosarcoma[J].Cancer Gene Ther,2021,28(12):1325-1338.
[30]Rothzerg E,Ingley E,Mullin B,et al.The hippo in the room:Targeting the Hippo signalling pathway for osteosarcoma therapies[J].J Cell Physiol,2021,236(3):1606-1615.
[31]Shor AC,Keschman EA,Lee FY,et al.Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival[J].Cancer Res,2007,67(6):2800-2808.
[32]Marley K,Gullaba J,Seguin B,et al.Dasatinib modulates invasive and migratory properties of canine osteosarcoma and has therapeutic potential in affected dogs[J].Transl Oncol,2015,8(4):231-238.
[33]Aggerholm-Pedersen N,Rossen P,Rose H,et al.Pazopanib in the treatment of bone sarcomas:Clinical experience[J].Transl Oncol,2020,13(2):295-299.
[34]Kany S,Woschek M,Kneip N,et al.Simvastatin exerts anticancer effects in osteosarcoma cell lines via geranylgeranylation and cJun activation[J].Int J Oncol,2018,52(4):1285-1294.
[35]Liu-Chittenden Y,Huang B,Shim JS,et al.Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP[J].Genes Dev,2012,26(12):1300-1305.
[36]马佳美,黄晓曦.Hippo信号通路在肝细胞癌诊治中作用的研究进展[J].中南大学学报:医学版,2021,46(6):637-643.
[37]Ferraiuolo M,Pulito C,Finch-Edmondson M,et al.Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines[J].Cancer Lett,2018(433):18-32.
[38]Luu AK,Viloria-Petit AM.Targeting mechanotransduction in osteosarcoma:A comparative oncology perspective[J].Int J Mol Sci,2020,21(20):7595.